BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

PHGE 11.12.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-14
Name of Upcoming Event:BiomX Third Quarter 2024 Earnings Conference Call
Full Press ReleaseSEC FilingsOur PHGE Tweets

About Gravity Analytica

Recent News

  • 12.16.2024 - BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards
  • 11.14.2024 - BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates
  • 11.12.2024 - BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

Recent Filings

  • 12.16.2024 - 8-K Current report
  • 11.14.2024 - EX-99.1 EX-99.1
  • 11.14.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

Download as PDFNovember 12, 2024 12:20pm EST

NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, November 14, 2024, at 8:00 a.m. ET, to report third quarter 2024 financial results and provide business and program updates.

To participate in the conference call, please dial 1-877-407-0724 (U.S) or 1-201-389-0898 (International). The live and archivedwebcastwill be available in the Investors section of the Company’s website atwww.biomx.com.

About BiomXBiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visitwww.biomx.com, the content of which does not form a part of this press release.

BiomX, Inc.Ben Cohenbenc@biomx.com

Primary Logo

Source: BiomX

Released November 12, 2024

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com